Second malignancy in 597 patients with ewing sarcoma of bone treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999.
The relative risk of second tumors in patients with Ewing sarcoma is controversial, and little is known about their treatment and outcome. The purpose of the current study was to define the incidence and features of second tumors among 597 long-term survivors of nonmetastatic Ewing sarcoma treated with adjuvant and neoadjuvant chemotherapy, radiotherapy, and/or surgery. The authors found that the risk of secondary malignancy after adjuvant or neoadjuvant treatment of Ewing sarcoma is higher than that after other childhood or adolescent cancers only after radiotherapy. Based on this, postoperative radiotherapy should be avoided when surgery with adequate margins is feasible.
Bacci
Gaetano
G
Department of Chemotherapy, Musculoskeletal Oncology at Istituto Ortopedico Rizzoli, Bologna, Italy. gaetano.bacci@ior.it
Longhi
Alessandra
A
Barbieri
Enza
E
Ferrari
Stefano
S
Mercuri
Mario
M
Briccoli
Antonio
A
Versari
Michela
M
Pignotti
Elettra
E
Picci
Piero
P
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000473:pathology* / Q000628:therapy; D002648:Child; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000209:etiology; D016609:Neoplasms, Second Primary / Q000473:pathology* / Q000628:therapy; D012512:Sarcoma, Ewing / Q000473:pathology* / Q000628:therapy; D015996:Survival Rate; D017741:Survivors; D016896:Treatment Outcome